Endocrine Abstracts

Raloxifene is a selective estrogen receptor modulator which has shown to decrease bone resorption, increase bone density and reduce vertebral fracture rate in women with postmenopausal osteoporosis. Recent studies have shown a decrease on breast cancer incidence after raloxifene treatment. Although the mechanism is not clear, its mixed agonist and antagonist properties in different tissues could partially explain this effect.Objective: To evaluate the ef...

Adiponectin and leptin have been described as potential contributors to bone metabolism. The effect of anticatabolic drugs on these adipokines and their relationship with bone metabolism have not been clearly clarified.Aims: (1) Evaluate adiponectin and leptin levels in osteoporosic postmenopausal women and their relationship with BMD, bone turnover and osteoclastogenesis markers. (2) Analyze changes on adiponectin and leptin levels after treatment with ...

Low concentrations of vitamin D leads to secondary hiperparathyroidism, bone loss, and an increase of osteoporotic fractures in populations at risk. Adequate vitamin D and calcium intake is considered an essential component of postmenopausal osteoporosis management. Several epidemiological studies have assessed the prevalence of low serum vitamin D concentrations, indicating that vitamin D inadequacy (<30 ng/ml) is a problem world-wide.Aims: To evalu...

Context: Postmenopausal osteoporosis (PMO) is associated with other comorbidities such as cardiovascular disease and impaired glucose homeostasis. Vitamin D insufficiency is highly prevalent, and may be a common link between these disorders. Recently, it has been shown that vitamin D may be involved in insulin resistance; however, this relationship has not been well evaluated in women with PMO.Objective: To assess the relationship between circulating lev...

Introduction: Sclerostin, produced by osteocytes, is a potent inhibitor of Wnt signaling and bone formation. The usefulness of its determination in clinical practice is not well established.Objectives: The aims of this study were to evaluate serum sclerostin levels in a cohort of Spanish posmenopausal women, and to analyze its relationship with bone metabolism.Methods: We measured serum sclerostin in 97 posmenopausal women using EL...

Introduction: Diabetes mellitus is associated with an increased risk of osteoporotic fractures, which leads to an increased risk of disability and frailty.Aims: To assess the prevalence of frailty in type 2 diabetes and to analyze the relationship with bone mineral density (BMD) and Trabecular Bone Score (TBS), fracture risk and prevalent fractures.Methods: We carried out a cross-sectional study of 75 diabetic patients (65±7 y...

Introduction: Hypophosphatasia (HPP) is an inherited disease, characterized by a non-tissue-specific alkaline phosphatase deficiency that leads to abnormal mineralization of bone tissue, which promotes fragility fractures. A defective muscle status could have important clinical repercussions on fracture risk. The aim of this work was to evaluate the relationship between bone and muscle compartment.Material and Methods: Observational cross-sectional study...

PRIMARA is the first observational study to describe the demographic and clinical profiles of adults with primary hyperparathyroidism (pHPT) receiving cinacalcet in daily clinics across European countries.Patients with pHPT aged ≥18 years without prior cinacalcet treatment were eligible. Initial cinacalcet dosage and subsequent dose changes were at the investigator’s discretion. Information on dosing, biochemistry and adverse drug reactions (A...

Introduction: Cardiovascular disease (CVD) is a health issue, worldwide, particularly in individuals with diabetes. The identification of CVD biomarkers can improve risk stratification. Sclerostin is a modulator of the Wnt/β-catenin signalling pathway in different tissues, and has recently been linked to vascular biology.Objectives: Our objective was to evaluate the relationship between circulating sclerostin levels and cardiovascular and non-cardio...

Introduction: Sclerostin is a glycoprotein expressed mainly by osteocytes, which acts as inhibitor of bone formation. However, several studies have shown an increase in serum levels of sclerostin in subjects with type 2 diabetes (T2D) and cardiovascular disease (CVD) suggesting an additional role of this protein at the vascular level. The hypothesis that sclerostin could be expressed by vascular smooth muscle cells (VSMCs) under calcifying conditions could justify this elevati...